major depressive disorder
Conditions
Interventions
Duloxetine
Aripiprazole
Sponsors
Department of Psychiatry, Fujita Health University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: DSM-4-TR:MDD Patients with treatment-resistant MDD: HAMD17>15:sufficient dose SSRI (ESC>15mg,PAR>30mg,SER>75mg,FLU>112,5mg) for more than 2 weeks. After that, the patients have no respose (HAMD17>15)to MIR 30mg/day for more than 2 weeks
Exclusion criteria
Exclusion criteria: Patient with the following disorders (based on DSM-IV-TR criteria): psychotic disorders, pervasive developmental disorders, bipolar disorder, obsessive-compulsive disorder, Axis-2 disorder. Patients with substance abuse or dependence (excluding nicotine and caffeine) meeting DSM-IV-TR criteria Patients taking MAO inhibitors with in14 days (or Patients treated with MAO inhibitors within 14 days) Patients taking pimozide Patients with allergies to escitalopram, duloxetine and aripiprazole Patients with QT interval prolongation Patients treated with ECT within the previous 6 months Patients having severe physical disease Patients who are pregnant or may become pregnant Patients at significant risk of suicide (having a score >3 on HAM-D item 11) Patients who had made suicide attempt within the past year
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Raing Scale for Depression | — |
Secondary
| Measure | Time frame |
|---|---|
| discontimuation rate, remission rate, adverse events | — |
Countries
Japan
Contacts
Public ContactTaro Kishi
Fujita Health University School of Medicine Department of Psychiatry
Outcome results
None listed